# Cover Letter for Leprosy Review

**Date:** December 31, 2024

**To:**
The Editor-in-Chief  
Leprosy Review  
Lepra, 28 Middleborough, Colchester, CO1 1TG, United Kingdom

**Subject:** Submission of Original Research Article - "An Integrated Multi-omics and Chemoinformatics Pipeline Identifies IDO1, PDL1, and JAK2 as Host-Directed Therapy Candidates for Leprosy"

---

Dear Editor,

I am pleased to submit our original research article entitled **"An Integrated Multi-omics and Chemoinformatics Pipeline Identifies IDO1, PDL1, and JAK2 as Host-Directed Therapy Candidates for Leprosy"** for consideration in *Leprosy Review*.

## Summary

Leprosy continues to cause significant morbidity through nerve damage and reactions despite effective multidrug therapy (MDT). This study presents a novel computational approach to systematically identify host-directed therapy (HDT) targets and repurposable drug candidates for leprosy, addressing the critical gap in preventing leprosy reactions and disability.

## Key Findings

1. **IDO1** (indoleamine 2,3-dioxygenase 1) was identified as a high-priority target, with strong literature validation for its role in leprosy immunosuppression through tryptophan catabolism.

2. **PD-L1/CD274** emerged as the second-ranked target, consistent with published evidence of PD-1-mediated T-cell exhaustion in lepromatous leprosy.

3. **JAK2** was prioritized, aligning with recent reports of tofacitinib efficacy for chronic ENL treatment.

4. **629 bioactive compounds** were identified, including 45 FDA-approved drugs as potential repurposing candidates.

## Significance and Novelty

This is the first systematic application of an integrated multi-omics and chemoinformatics pipeline to leprosy HDT target discovery. Our findings provide:

- **Translational relevance:** Multiple FDA-approved drugs (JAK inhibitors) identified with published clinical evidence for leprosy reactions
- **Mechanistic insights:** Convergence between leprosy and tuberculosis HDT targets suggests shared mycobacterial immune evasion strategies
- **Clinical applicability:** Prioritized targets (IDO1, PDL1, JAK2) have established roles in leprosy immunopathology with clear therapeutic rationales

The computational approach overcomes limitations of *M. leprae*'s inability to be cultured *in vitro* and provides a rational framework for developing adjunctive immunotherapies to prevent leprosy-associated disability.

## Relevance to Leprosy Review

This manuscript aligns perfectly with *Leprosy Review*'s mission to publish innovative research advancing leprosy control and treatment. Our work addresses:

- **Unmet clinical need:** Novel therapies for leprosy reactions beyond corticosteroids and thalidomide
- **Global health priority:** Preventing disability in the post-MDT era
- **Translational potential:** Repurposable FDA-approved drugs for rapid clinical translation

## Manuscript Details

- **Word Count:** 2,993 words (excluding abstract, references, tables)
- **Tables:** 3 (Top 10 targets, Drug candidates, Literature validation)
- **Figures:** 4 (Target prioritization, Compound distribution, Potency landscape, Pathway heatmap)
- **References:** 35 (Vancouver style)
- **Supplementary Files:** 2 (Complete target list, Complete compound list)

## Declarations

- This manuscript is original and has not been published elsewhere
- The manuscript is not under consideration by any other journal
- All authors have approved the submission
- No conflicts of interest to declare
- No funding received for this study
- All data and code are publicly available at https://github.com/hssling/Leprosy_drug_discovery

## Author Information

**Dr. Siddalingaiah H S**  
Professor, Department of Community Medicine  
Shridevi Institute of Medical Sciences and Research Hospital  
Tumkur â€“ 572106, Karnataka, India  
Email: hssling@yahoo.com  
Phone: +91-8941087719  
ORCID: 0000-0002-4771-8285

I believe this work will be of significant interest to the leprosy research community and look forward to your favorable consideration.

Sincerely,

**Dr. Siddalingaiah H S**  
Corresponding Author

---

**Suggested Reviewers:**

1. **Dr. Diana Lockwood**  
   London School of Hygiene & Tropical Medicine, UK  
   Email: diana.lockwood@lshtm.ac.uk  
   *Expertise: Leprosy immunology, leprosy reactions*

2. **Dr. Thomas Gillis**  
   National Hansen's Disease Program, USA  
   Email: tgillis@hrsa.gov  
   *Expertise: M. leprae genomics, drug discovery*

3. **Dr. Annemieke Geluk**  
   Leiden University Medical Center, Netherlands  
   Email: a.geluk@lumc.nl  
   *Expertise: Leprosy immunology, host-pathogen interactions*
